How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

370 results for

Long Acting Nitroglycerin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long Acting Nitroglycerin

Long Acting Nitroglycerin Long Acting Nitroglycerin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Long Acting Nitroglycerin Long (...) Acting Nitroglycerin Aka: Long Acting Nitroglycerin , Long Acting Nitrates , Transdermal Nitroglycerin , Transdermal Glyceryl Trinitrate , Isosorbide , Nitroglycerin Ointment , Isosorbide Mononitrate , Isosorbide Dinitrate From Related Chapters II. General Need 10-12 hours free interval per day Not proven to reduce of future events III. Indications Chronic Not indicated for acute IV. Preparations: Long acting Isosorbide Dinitrate (Isordil) Reg: 10 to 40 mg PO tid (7am, 12 noon, 5pm) SR: 40-80 mg PO

2018 FP Notebook

2. Nitroglycerin

coronary angiography who presented with frequent angina episodes were randomly assigned to 1-month treatment with nicorandil 10 mg, 2 2015 10. A Novel Non-Antibiotic Nitroglycerin Based Catheter Lock Solution for the Prevention of Intraluminal Central Venous Catheter Infections in Cancer Patients. Background: For long-term central lines (CL), the lumen is the major source of central line associated bloodstream infections (CLABSI). Current standard of care for maintaining catheter patency includes (...) in Cardiovascular Therapeutics. , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26510043 DOI: [Indexed for MEDLINE] Free full text Publication types 2015 14. A centrally acting antihypertensive, clonidine, combined to a venous dilator, nitroglycerin , to handle severe pulmonary edema. A patient, with known left ventricular failure presented with severe pulmonary edema, an ejection fraction of 10% to 15%, knee mottling, and lactates of 7 mM L⁻¹. He was treated with unusually high-dose

2018 Trip Latest and Greatest

3. Topical Nitroglycerin for Peripheral Circulation and Wound Healing in the Elderly

. PubMed: PM11825312 15. Abrams J. Nitroglycerin and long-acting nitrates in clinical practice. Am J Med. 1983 Jun 27;74(6B):85-94. PubMed: PM6407316 16. Olivari MT, Cohn JN. Cutaneous administration of nitroglycerin: a review. Pharmacotherapy. 1983 May;3(3):149-57. PubMed: PM6410359 (...) Topical Nitroglycerin for Peripheral Circulation and Wound Healing in the Elderly Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Long Acting Nitroglycerin

Long Acting Nitroglycerin Long Acting Nitroglycerin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Long Acting Nitroglycerin Long (...) Acting Nitroglycerin Aka: Long Acting Nitroglycerin , Long Acting Nitrates , Transdermal Nitroglycerin , Transdermal Glyceryl Trinitrate , Isosorbide , Nitroglycerin Ointment , Isosorbide Mononitrate , Isosorbide Dinitrate From Related Chapters II. General Need 10-12 hours free interval per day Not proven to reduce of future events III. Indications Chronic Not indicated for acute IV. Preparations: Long acting Isosorbide Dinitrate (Isordil) Reg: 10 to 40 mg PO tid (7am, 12 noon, 5pm) SR: 40-80 mg PO

2015 FP Notebook

5. [The effect of five different long-acting nitroglycerine derivatives on angina pectoris]. (PubMed)

[The effect of five different long-acting nitroglycerine derivatives on angina pectoris]. 4627249 1972 11 16 2013 11 21 0012-0472 97 40 1972 Oct 06 Deutsche medizinische Wochenschrift (1946) Dtsch. Med. Wochenschr. [The effect of five different long-acting nitroglycerine derivatives on angina pectoris]. 1479-84 Kaltenbach M M Tiedemann I I Schellhorn W W ger Clinical Trial Controlled Clinical Trial Journal Article Randomized Controlled Trial Wirksamkeit fünf verschiedener langwirksamer (...) Nitroderivate auf die Angina pectoris. Germany Dtsch Med Wochenschr 0006723 0012-0472 0 Delayed-Action Preparations 0 Placebos 0 Vasodilator Agents 10L39TRG1Z Pentaerythritol Tetranitrate G59M7S0WS3 Nitroglycerin IA7306519N Isosorbide Dinitrate YQE403BP4D Phenobarbital IM Administration, Oral Adult Aged Angina Pectoris drug therapy Clinical Trials as Topic Delayed-Action Preparations Electrocardiography Exercise Test Humans Isosorbide Dinitrate therapeutic use Male Middle Aged Nitroglycerin therapeutic use

1972 Deutsche medizinische Wochenschrift (1946)

6. Intravenous Nitroglycerine in STEMI, with data: Avoid its use if giving tPA

International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85. 252. Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J 1985;110:216-24. 253. Winbury MM. Redistribution of left ventricular blood flow produced by nitroglycerin: an example of integration of the macroand (...) Intravenous Nitroglycerine in STEMI, with data: Avoid its use if giving tPA Dr. Smith's ECG Blog: Intravenous Nitroglycerine in STEMI, with data: Avoid its use if giving tPA Thursday, September 11, 2014 If you are giving tPA to patients with STEMI, it is wise to avoid IV nitroglycerine. I am revisiting this topic because of . This patient was very hypertensive, and thus needed something to control BP. But I would advise against nitroglycerine. This is data that very few cardiologists are aware

2014 Dr Smith's ECG Blog

7. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 (...) February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 Free Access article Share on Jump to Free Access article Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association , MD, MPH, FAHA, Chair , MD , MD, MPH, FAHA , MD , MD, FAHA , MD, FAHA , MSN, RN, CPNP , MD , MD, FAHA , MD , MD, PhD , MD, PhD , and MD, FAHA MD, FAHA, Co-ChairOn behalf of the American Heart Association Rheumatic

2017 American Heart Association

8. Long-acting Glyceryl Trinitrate in Angina Pectoris of Out-patients (PubMed)

Long-acting Glyceryl Trinitrate in Angina Pectoris of Out-patients 14432980 1998 11 01 2018 12 01 0007-1447 1 5165 1960 Jan 02 British medical journal Br Med J Long-acting glyceryl trinitrate in angina pectoris of out-patients. 38 PILKINGTON T R TR PURVES M J MJ eng Journal Article England Br Med J 0372673 0007-1447 0 Nitrites G59M7S0WS3 Nitroglycerin OM Angina Pectoris therapy Immunotherapy, Adoptive Nitrites therapy Nitroglycerin Outpatients ANGINA PECTORIS/therapy NITRITES/therapy 1960 1 2

Full Text available with Trip Pro

1960 British medical journal

9. The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women

to improve the IUD insertion experience for both patient and provider. The investigators hypothesis is that nitroglycerin ointment will decrease the pain associated with IUD insertion. Condition or disease Intervention/treatment Phase Contraception Pain Drug: Insertion of nitroglycerin ointment Drug: Insertion of placebo ointment Not Applicable Detailed Description: Increasing acceptability and use of long acting reversible contraceptive methods like the intrauterine device (IUD) is an important strategy (...) and Science University. Recruitment status was: Recruiting First Posted : December 12, 2011 Last Update Posted : February 6, 2013 Sponsor: Oregon Health and Science University Collaborators: American College of Obstetricians and Gynecologists Bayer Information provided by (Responsible Party): Elizabeth Micks, Oregon Health and Science University Study Details Study Description Go to Brief Summary: Increasing ease of access of long-acting birth control methods, like intrauterine devices (IUDs

2011 Clinical Trials

10. Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure. (PubMed)

Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure. Vasodilators are known to be effective in improving the hemodynamics of congestive heart failure by increasing cardiac output and reducing left ventricular filling pressure (LVFP). Long acting agents are needed to augment the practicality and availability of chronic vasodilator therapy. In the present study the vascular effects of chewable isosorbide dinitrate (CHIS (...) ), sublingual nitroglycerin (NTG) and placebo (P) were compared in eight patients with high LVFP due to heart failure. Patients with LVFP (pulmonary wedge pressure) over 14 mm Hg were given CHIS, 10 mg, NTG, 0.6 mg, and P, two chewable tablets, in random fashion. Heart rate (HR), blood pressure (BP) and LVFP were monitored for three hours after each drug. HR was not significantly affected by any drug, although it rose slightly after NTG and fell after CHIS. Significant reduction of BP occurred only after

1975 Circulation

11. Management of stable angina

to quantify the degree of bias with any certainty. SIGN requires that all those involved in the work of guideline development should declare all financial interests, whether direct or indirect, annually for as long as they are actively working with the organisation. By being explicit about the influences to which contributors are subjected, SIGN acknowledges the risk of bias and makes it possible for guideline users or reviewers to assess for themselves how likely it is that the conclusions and guideline (...) , if appropriate. 9 Where high perioperative risk is identified, a strategy for risk reduction should be agreed. This will require teamwork and good communication between surgeon, anaesthetist, perioperative physician and cardiologist. 6.1.2 FUNCTIONAL CAPACITY Functional capacity has been shown to predict perioperative and long-term cardiac events and should be part of the preoperative assessment of patients with CAD undergoing major surgery. 205,206 Functional capacity can be expressed in metabolic

2018 SIGN

12. Guidelines on Diagnosis and Management of Syncope

5.6.5.1 Long QT syndrome 1926 5.6.5.2 Brugada syndrome 1926 5.6.5.3 Other forms 1927 6. Special issues 1927 6.1 Syncope in patients with comorbidity and frailty 1927 6.1.1 Comorbidity and polypharmacy 1927 6.1.2 Falls 1928 6.1.3 Cognitive assessment and physical performance tests 1928 6.2 Syncope in paediatric patients 1929 6.2.1 Diagnostic evaluation 1929 6.2.2 Therapy 1929 7. Psychogenic transient loss of consciousness and its evaluation 1929 7.1 Diagnosis 1929 7.1.1 Historical criteria for attacks (...) recorder ISSUE International Study on Syncope of Unknown Etiology L-DOPA L-3,4-dihydroxyphenylalanine LOC Loss of consciousness LQTS Long QT syndrome LVEF Left ventricular ejection fraction MRI Magnetic resonance imaging NYHA New York Heart Association OH Orthostatic hypotension PC-Trial Physical Counterpressure Manoeuvres Trial PCM Physical counter-pressure manoeuvres PNES Psychogenic non-epileptic seizures POST Prevention of Syncope Trial POTS Postural orthostatic tachycardia syndrome PPS Psychogenic

Full Text available with Trip Pro

2018 European Society of Cardiology

13. Isosorbide mononitrate

0261505 0300-9033 IA7306519N Isosorbide Dinitrate IM Adult Esophageal and Gastric Varices complications etiology Female Gastrointestinal Hemorrhage etiology prevention & control Humans Isosorbide Dinitrate 1993 2. [Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide -5- mononitrate ]. 16353064 2005 12 14 2006 04 04 2017 03 10 0022-9040 45 11 2005 Kardiologiia Kardiologiia (...) [Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide -5- mononitrate ]. 42-5 To assess efficacy (...) and tolerability of a novel drug form of isosorbide -5- mononitrate in patients with ischemic heart disease and stable effort angina as compared with common isosorbide dinitrate pills. Patients with stable class II-III effort angina (n=30) were included into a randomized crossover

2018 Trip Latest and Greatest

14. ESC/ESH Management of Arterial Hypertension

and Prognosis in the Elderly SCORE Systematic COronary Risk Evaluation SHEP Systolic Hypertension in the Elderly Program SPC Single-pill combination SPRINT Systolic Blood Pressure Intervention Trial STOP-H Swedish Trial in Old Patients with Hypertension SUCH Sustained uncontrolled hypertension Syst-China Systolic Hypertension in China Syst-Eur Systolic Hypertension in Europe TIA Transient ischaemic attack TTE Transthoracic echocardiography VALUE Valsartan Antihypertensive Long-term Use Evaluation VEGF (...) in a binary way in CV risk assessment systems (e.g. diabetes, yes/no). This does not reflect the impact of the severity or duration of concomitant diseases on total CV risk. For example, long-standing diabetes is clearly associated with high risk, whereas the risk is less certain for recent-onset diabetes. A third conundrum specific to hypertension is what BP value to use in CV risk assessment in a patient who is receiving treatment for hypertension. If treatment was commenced recently, it seems

Full Text available with Trip Pro

2018 European Society of Cardiology

15. Management of Cardiovascular Diseases during Pregnancy

Prevention of hypertension and pre-eclampsia 3207 10.4 Management of hypertension in pregnancy 3208 10.4.1 Background 3208 10.4.2 Non-pharmacological management 3208 10.4.3 Pharmacological management 3208 10.5 Delivery 3208 10.6 Prognosis after pregnancy 3209 10.6.1 Blood pressure post-partum 3209 10.6.2 Hypertension and lactation 3209 10.6.3 Risk of recurrence of hypertensive disorders in a subsequent pregnancy 3209 10.6.4 Long-term cardiovascular consequences of gestational hypertension 3209 10.6.5 (...) 5-HT1A 5-hydroxytryptamine (serotonin) HTAD Heritable thoracic aortic disease ICD Implantable cardioverter-defibrillator ICU Intensive care unit IE Infective endocarditis INR International normalized ratio i.v. Intravenous KLH Keyhole limpet haemocyanin LMWH Low molecular weight heparin LQTS Long QT syndrome LV Left ventricular LVEF Left ventricular ejection fraction MCS Mechanical circulatory support mGy Milligray MI Myocardial infarction MR Mitral regurgitation MRA Mineralocorticoid receptor

Full Text available with Trip Pro

2018 European Society of Cardiology

16. Male Sexual Dysfunction

2 and 4 years after radical prostatectomy. J Urol, 2009. 181: 731. 79. Incrocci, L., et al. Pelvic radiotherapy and sexual function in men and women. J Sex Med, 2013. 10 Suppl 1: 53. 80. Morgia, G., et al. Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I(125) implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Aging Male, 2016. 19: 15. 81. Stember, D.S., et al. The concept of erectile function preservation (...) prostatectomy. J Urol, 2013. 189: 2229. 133. Corona, G., et al. The safety and efficacy of Avanafil, a new 2nd generation PDE5i: Comprehensive review and meta-analysis. Expert Opin Drug Saf, 2016. 15(2)237. 134. Cui, H., et al. Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia, 2015. 47(1)20. 135. Montorsi, F., et al. Recovery of spontaneous erectile function after

2019 European Association of Urology

17. Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation

Monitoring 24 6.3 Ambulation 24 6.4 Length of stay 24 6.5 Special patient subsets 25 6.5.1 Patients taking oral anticoagulation 25 6.5.2 Elderly patients 25 6.5.3 Renal dysfunction 25 6.5.4 Non-reperfused patients 25 6.5.5 Patients with diabetes 26 6.6. Risk assessment 28 6.6.1 Clinical risk assessment 28 6.6.2 Non-invasive imaging in management and risk stratification 28 7. Long-term therapies for ST-segment elevation myocardial infarction 29 7.1 Lifestyle interventions and risk factor control 29 7.1.1 (...) Smoking cessation 29 7.1.2 Diet, alcohol, and weight control 29 7.1.3 Exercise-based cardiac rehabilitation 30 7.1.4 Resumption of activities 30 7.1.5 Blood pressure control 30 7.1.6 Adherence to treatment 30 7.2 Antithrombotic therapy 30 7.2.1 Aspirin 30 7.2.2 Duration of dual antiplatelet therapy and antithrombotic combination therapies 31 7.3 Beta-blockers 32 7.3.1 Early intravenous beta-blocker administration 32 7.3.2 Mid- and long-term beta-blocker treatment 32 7.4 Lipid-lowering therapy 32 7.5

Full Text available with Trip Pro

2017 European Society of Cardiology

18. CRACKCast E152 – Cardiovascular Drugs

will be elevated for up to 1 week after Fab fragments administration, with values often greater than 100 ng/ mL once Fab fragments have been administered. The significant protein binding and large volumes of distribution of digoxin suggest that hemodialysis, hemoperfusion, and exchange transfusion are ineffective. The long half-lives have therapeutic implications for temporizing measures such as pacemakers, atropine, and antidysrhythmic drugs compared to the more definitive treatment of Fab fragments. Beta (...) Ringer’s Temporize with IV atropine if HR < 50 bpm Give 3-6 g Calcium Gluconate over ~15 mins for bradycardia and hypotension Consider Glucagon: Glucagon has both inotropic and chronotropic effects and does not depend on beta-adrenergic receptors for its action; therefore, it has long been used for beta-blocker toxicity. It stimulates the production of intracellular cyclic adenosine monophosphate independently of the beta-adrenergic receptor. Furthermore, it helps counteract the hypoglycemia induced

2018 CandiEM

19. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm

approach to the patient, (2) treatment of the patient with an AAA, (3) anesthetic considerations and perioperative management, (4) postoperative and long-term management, and (5) cost and economic considerations. Results Along with providing guidance regarding the management of patients throughout the continuum of care, we have revised a number of prior recommendations and addressed a number of new areas of significance. New guidelines are provided for the surveillance of patients with an AAA (...) of anesthetic technique and agent 43 Anesthetic considerations in the patient with a ruptured aneurysm 44 Antibiotic prophylaxis 44 Intraoperative fluid resuscitation and blood conservation 44 Cardiovascular monitoring 44 Maintenance of body temperature 45 Role of the ICU 45 Nasogastric decompression and perioperative nutrition 46 Prophylaxis for deep venous thrombosis 46 Postoperative blood transfusion 46 Perioperative pain management 46 POSTOPERATIVE AND LONG-TERM MANAGEMENT 47 Late outcomes 47 Endoleak

2018 Society for Vascular Surgery

20. Sirens to Scrubs: Acute Coronary Syndromes, Part Two – To the Lab!

with ACS. Nitroglycerin administration results in decreased myocardial oxygen consumption through several mechanisms. As a smooth muscle relaxant, it causes: Venodilation, which reduces the amount of blood returning to the heart (preload) Reduces stress on the ventricular wall Reduces the amount of volume in the ventricles during diastole (after the blood has been pumped out), which is the time in which the heart is perfused. High volumes in the ventricles during diastole act to compress the small (...) contested, with some studies potentially suggesting an association with a higher dose (324mg) of Aspirin and significant in-hospital bleeding when compared with a lower dose (162mg), despite an apparent equal clinical effect. 4 The dose employed by ambulance services in Canada and internationally is variable, with doses ranging from 150mg to 325mg as recommended by the AHA and ESC. Sublingual nitroglycerin, or glyceryl trinitrate, is the primary vasodilating agent used in prehospital care for patients

2018 CandiEM

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>